多肿瘤标志物蛋白芯片在肺癌诊疗中的应用价值

Value of Multi-tumor Markers Protein Biochip in the Diagnosis of Lung Cancer

目的探讨多肿瘤标志物蛋白芯片在肺癌诊疗中的应用价值。方法采用多肿瘤标志物蛋白芯片检测肺癌患者157例、良性肺病177例、健康体检者41例血清中的12种肿瘤标志物(CA125、CA19-9、Ferritin、CA153、CA242、CEA、AFP、NSE、PSA、f-PSA、HGH、β-HCG)。结果肺癌组肿瘤标记物阳性率为92.36%,良性肺病组为76.83%,健康对照组为7.32%,差异有统计学意义(P<0.01)。肺癌组血清中肿瘤标记物CEA、CA242阳性率与良性肺病组、健康对照组比较,差异均有统计学意义(均P<0.05),而β-HCG、AFP、f-PSA、PSA、HGH等差异无统计学意义(均P>0.05)。肺癌组血清中肿瘤标记物CA19-9、NSE、CEA、CA242、CA125、CA153水平显著高于肺良性病变组和健康对照组(均P<0.05),而β-HCG、f-PSA、PSA、HGH等差异无统计学意义(P>0.05)。结论多肿瘤标志物蛋白芯片仅可用于肺癌的早期辅助诊断,并不能作为肺癌的确诊指标。

Objective To evaluate the clinical value of multi-tumor markers protein biochip in the diagnosis of lung cancer. Methods Serum CA125, CA19-9, Ferritin, CA15-3, CA242, CEA, AFP, NSE, PSA, f-PSA, HGH,β-HCG were detected by multi-tumor markers protein biochip in 157 patients with lung cancer, 177 patients with benign lung disease, and 41 healthy people in control group. Results The positive rate of 12 tumor markers （ 92 . 36%） in lung cancer was significant higher than that in benign lung disease （76. 83%） and healthy people （7. 32%）（all P〈0. 01）. The positive rate of CEA and CA242 in lung cancer showed significant differences compared with benign lung disease and healthy people （ all P〈0. 05）, but no significant differences inβ-HCG, AFP, f-PSA, PSA, HGH. Serum levels of CA19-9, NSE, CEA, CA242, CA125, CA153 were significant higher in lung cancer than that in benign lung disease and healthy people （all P 〈0.05）, but no significant differences in β-HCG, f-PSA, PSA, HGH （all P 〉0. 05）. Conclusion Multi-tumor markers biochip might contribute to the early diagnosis for lung cancer, but not to be a definite diagnosis biomarker.